Table 1 Clinical characteristics in the study groups. Cell count is n/μl CSF (reference range < 4 /μl). Albumin is mg/l (reference range < 400 mg/l)
From: Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
Patient no. | Disease phase | CSF cell count | CSF Albumin | |
|---|---|---|---|---|
Polynuclear | Mononuclear | |||
1 | Acute phase | 31 | 43 | 560 |
After treatment | 0 | 2 | 259 | |
2 | Acute phase | 445 | 80 | 3132 |
After treatment | 0 | 15 | 215 | |
3 | Acute phase | 364 | 80 | 2546 |
After treatment | 2 | 37 | 143 | |
4 | Acute phase | 310 | 12 | 665 |
After treatment | 46 | 4 | 211 | |
5 | Acute phase | 9000 | 900 | 1650 |
After treatment | missing | missing | 1710 | |
6 | Acute phase | 3400 | 744 | missing |
After treatment | 17 | 60 | 361 | |